prognostic indicators

Four risk prediction models have been shown to accurately select the highest risk smokers for lung cancer screening.
A recent study found that diagnosis-to-treatment interval may be linked with prognostic clinical factors and event-free survival in newly diagnosed diffuse large B-cell lymphoma.
Major advances in the biology and treatment of patients with CLL have prompted the International Workshop on CLL to evaluate and revise the criteria for their consensus guideline in this disease setting.
Limited evidence exists that supports the use of most circulating tumor DNA assays in the diagnosis or management of early-stage or advanced solid tumors, according to an expert review.
Human epidermal growth factor receptor 2 may be a potential marker of poor prognosis in patients with unclassified ovarian cancer, according to a recent meta-analysis.
A recent study examined whether the Lung Immune Prognostic Index was associated with resistance to immunotherapy in patients with advanced non-small cell lung cancer.
Higher scores on a multi-biomarker disease activity system are associated with hospital infection, myocardial infarction, and coronary heart disease events in older patients with rheumatoid arthritis.
A recent study identified patient characteristics that help predict poor 3-year survival in newly diagnosed standard-risk multiple myeloma.
High levels of a specific enzyme are linked with lower survival rates in patients with multiple myeloma, according to a new study.
Upregulation of a specific protein may be an indicator of radiation resistance in patients with resected non-small cell lung cancer who received radiotherapy.